Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Hepatitis awareness

Hepatitis awareness

Hepatitis is usually caused by a viral infection but can also result from liver damage caused by drinking alcohol. People infected with the hepatitis A or B virus usually recover in a couple of months. But over 200,000 people in the UK are affected by Hepatitis C. After years or even decades, infection can lead to liver damage that is potentially life-threatening. On this page are a number of articles related to hepatitis, including coverage of the advent of new and highly effective drugs for Hepatitis C, how they work and also the struggle for the health system to afford them.

Micrograph of cirrhosis of the liver

Statins benefit patients with hepatitis B and C related cirrhosis

Statins may benefit patients with cirrhosis of the liver caused by the Hepatitis B (HBV) or Hepatitis C (HCV) virus, according to the results of a Taiwan study published in Hepatology[1] (online, 20 March 2017).

Winners of the 2015 Care Awards Audience Choice Awards. From left, Ryan Buchanan, Pembe Hassan-Hicks and Kevin Noble

Community pharmacy helps diagnose people with hepatitis C infection, study shows

By

Community pharmacists have the potential to identify people with undiagnosed hepatitis C infection, according to research published in Clinical Pharmacist.

Close-up of a person taking a dry-blood spot test

Integrating community pharmacy testing for hepatitis C with specialist careSubscription

By Ryan Buchanan, Pembe Hassan-Hicks, Kevin Noble, Leonie Grellier, Julie Parkes, Salim I Khakoo

Many patients with hepatitis C virus (HCV) infection lie undiagnosed and a significant proportion of patients that have been identified are disengaged from specialist services. The Isle of Wight (IOW) typifies this issue, with an estimated 200 undiagnosed patients with HCV infection and a small number of known cases engaged with specialist services. Aim: To reduce the burden of undiagnosed HCV on the IOW and link new diagnoses directly ...

Liver cancer

EMA extends review of antivirals for hepatitis CSubscription

The European Medicines Agency is extending its review of direct-acting antiviral treatments for hepatitis C to look at evidence that shows they are associated with liver cancer recurrence.

European Medicines Agency headquarters

EMA to review safety of direct-acting antivirals after reports of hepatitis B reactivationSubscription

The European Medicines Agency is to review the safety of direct-acting antivirals used to treat patients with chronic hepatitis C infection.

Targeting Hepatitis C: How new treatments work

Targeting hepatitis C — how new treatments workSubscription

By

There are >185 million people with hepatitis C infection worldwide but new treatments mean that most people with access to therapy can now be cured. 

Pulmonary arterial hypertension with PegasysSubscription

Pulmonary arterial hypertension has been added as a adverse event with unknown frequency in the summary of product characteristics for Pegasys (peginterferon alfa-2a; Roche). It states that cases of pulmonary arterial hypertension have been reported in patients with risk factors such as portal hypertension, HIV infection and cirrhosis.

More on Hepatitis Awareness

Micrograph of cirrhosis of the liver

Statins benefit patients with hepatitis B and C related cirrhosis

Statins may benefit patients with cirrhosis of the liver caused by the Hepatitis B (HBV) or Hepatitis C (HCV) virus, according to the results of a Taiwan study published in Hepatology[1] (online, 20 March 2017).

The US Food and Drug Administration (FDA)

FDA approves first direct-acting antivirals for adolescents with hepatitis C

The US Food and Drug Administration (FDA) has approved Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) for the treatment of hepatitis C in adolescents aged 12–17 years.

Medicines on shelf

Global spend on medicines to reach US$1.5 trillion by 2020, analysts project

The global spend on medicines is predicted to reach US$1.5 trillion by 2020 — a rise of 33% from 2016 figures, according to a financial forecast by the QuintilesIMS Institute.

We should aim to achieve complete elimination of hepatitis CSubscription

By

I read the letters from Charles Gore (Clinical Pharmacist 2016;8:232) and Anja St. Clair Jones (Clinical Pharmacist 2016;8:264) ...

NHS England tried hard to manage funding of new hepatitis C drugsSubscription

By

I read with interest the letter from Charles Gore of The Hepatitis C Trust asking why NHS England is treating people living with hepatitis C as exceptional cases and has capped the access to medicines that can eradicate the infection in most cases.

Winners of the 2015 Care Awards Audience Choice Awards. From left, Ryan Buchanan, Pembe Hassan-Hicks and Kevin Noble

Community pharmacy helps diagnose people with hepatitis C infection, study shows

By

Community pharmacists have the potential to identify people with undiagnosed hepatitis C infection, according to research published in Clinical Pharmacist.

Why are hepatitis C patients treated differently by NHS England?Subscription

By

NHS England’s decision to cap access to National Institute for Health and Care Excellence (NICE) approved hepatitis C treatments has been attributed to their cost. These antiviral medicines have led to vast costs for national healthcare systems and huge profits for the pharmaceutical industry. So it is understandable that the mainstream media and general public assume that the cost to the NHS (either per patient or in absolute terms) is prohibitive.

Hepatitis virions micrograph

EMA recommends combination therapies for chronic hepatitis C virus

By

Two new combination therapies that have the potential to cure patients with long-term hepatitis C virus infection and rule out the need for interferon are being recommended for approval across the EU.

Micrograph of a liver with hepatitis C

Viral suppression restores life expectancy in hepatitis C-related cirrhosisSubscription

Study shows sustained virologic response in patients with hepatitis C and cirrhosis dramatically improves survival.

Charles Gore, chief executive of The Hepatitis C Trust

The Hepatitis C Trust considers legal action over cap on NHS patients allowed to seek treatment

By

NHS England is limiting treatment with new drugs for hepatitis C to 10,000 of the most in-need patients, prompting The Hepatitis C Trust to consider seeking a judicial review of the decision.

More on Hepatitis Awareness

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

Pharmaceutical Journal Jobs

More jobs